Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INCB 057643

Next Previous
Drug Profile

INCB 057643

Alternative Names: BETi; INCB 57643; INCB057643; LIMBER-103

Latest Information Update: 07 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics; Oxazines; Pyridines; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelofibrosis
  • Phase I Myelodysplastic syndromes
  • Discontinued Cancer

Most Recent Events

  • 07 Jul 2025 Pharmacodynamics data from a preclinical trial in myelofibrosis presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 03 Jun 2025 Incyte Corporation completes a phase I bioavailability trial (In volunteers) in USA (PO, Tablet) (NCT06941077)
  • 09 May 2025 M.D. Anderson Cancer Center withdrawn a phase II trial prior to enrollment in Myelofibrosis (Combination therapy)due to zero participant accrual (NCT06619522)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top